Navigation Links
YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
Date:1/5/2009

MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has received clearance from Canadian regulatory authorities to initiate two Phase II, double-blind, randomized trials for nimotuzumab, its EGFR-targeting antibody, in combination with radiation-based treatments. The Company will conduct a Phase II trial in approximately 128 patients with non-small cell lung cancer (NSCLC) and a Phase II trial in approximately 88 patients with brain metastases from NSCLC. Enrolment for both trials is expected to be initiated in Canada in the first quarter of calendar 2009 and YM anticipates adding sites from other countries into the trials.

"Conducting randomized, controlled studies in these particularly challenging and neglected patient populations will substantially augment the already extensive late-stage clinical program being pursued by the global consortium of companies developing nimotuzumab. The results from these trials could contribute significantly to the data package for nimotuzumab which will be used to expand its approval across international markets. Specific to our North American regulatory strategy, these trials form part of the registration program and should generate robust data relatively rapidly," said David Allan, Chairman and CEO of YM BioSciences. "We have focused on cancers typically treated with radiation-containing regimens because the combination has demonstrated the potential to maximize the benefits of radiotherapy and increase survival and quality of life while avoiding the toxic side-effects of both chemotherapy/radiation combinations and the debilitating and dangerous side effects of other EGFR-targeting drugs."

Non-small cell lung cancer trial

This randomized, double-blind, Phase II study will evaluate nimot
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... USA (PRWEB) November 26, 2014 Biomedical ... accuracy, additive systems to enable 3D manufacture at the ... road conditions are among finalists in nine categories for ... The awards are sponsored by SPIE, the international ... Media . , Winners will be announced by industry ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is a professional and in-depth research report on ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... November 26, 2014 On January, 14, ... Baltimore and Washington D.C. science community to the UMBC ... event, sponsored by the Protein Society, will take place ... Center, Room 312. Through discussion, presentations and workshops, ... importance of proteins, their role in the industry and ...
Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Project will advance novel platform for treatment of Spinal ... 12 PTC Therapeutics, Inc. (PTC) and the Spinal ... their research collaboration in which the SMA Foundation will ... This is the second continuation of the collaboration ...
... an,immunology-focused biotech company dedicated to the development of,therapeutic ... CHF,62.5 million (USD 54.8 million) to take back ... fully human monoclonal antibody to CD3 and,interferon-gamma, respectively) ... was led by BZ Bank Aktiengesellschaft. , ...
... VRUS ), a clinical stage pharmaceutical company ... treat viral infections, reported financial results and operational highlights ... Financial Results Revenues were $1.9 million during the quarter ... the quarter ended March 31, 2008 and reflect the ...
Cached Biology Technology:PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 3NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 3Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 4Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 5Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 6Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 7Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 8
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/11/2014)... , Nov. 11, 2014  Forensicon, Inc., a ... firm, is pleased to announce the promotion of ... Director of Digital Forensics. In Schiff,s new role as ... the team of digital forensics examiners and provide leadership ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... reveals the interaction of genetic and environmental factors such ... explained Dr. Matthias Elstner of the Neurological Clinic of ... study. In addition, this genome-wide expression and association study ... both disease risk and therapy response ( Annals of ...
... not all the same when it comes to risk of ... researcher shows key differences among Hispanic populations that doctors should ... cardiovascular disease in this large and growing subset of the ... January 19, 2009 Journal of the American College of ...
... new quarterly newsletter for academic librarians and information professionals. ... developments at OUP and across the publishing world. ... and member of the Editorial Team said: ,After careful ... developed a strong and broad source of information for ...
Cached Biology News:Genetic risk factor identified for Parkinson's disease 2Crucial differences found among Latino populations facing heart disease risks 2
... mini, SSM3 & SSM4, Small space saving design ... , Choice of two models: , - 3D ... , Digital speed control and built-in timer ... ,These compact rockers are ideal where gentle mixing is ...
... for high-yield protein expression ,The ... a high-yielding clone of Sf9 cells. Pre-adapted ... Cell Medium, these cells are recommended for ... baculovirus infection or transfection of appropriate vectors. ...
... Gene Knockout System provides optimized reagents and ... of bacterial genes by insertion of group ... ability of group II introns and utilizes ... TargeTron group II intron for specific insertion ...
... antibody raised against a partial recombinant MAK. ... ~ 457 a.a) partial recombinant protein with GST ... Accession: BC039825 ... OMIM: 154235, GeneID: ...
Biology Products: